Diagnostic, prognostic and predictive biomarkers in prostate cancer / / edited by Carsten Stephan.

• TeilnehmendeR: Stephan, Carsten,
• Place / Publishing House: Basel, Switzerland : : MDPI - Multidisciplinary Digital Publishing Institute,, 2017.
• Year of Publication: 2017
• Language: English
• Physical Description: 1 online resource (414 pages) :; illustrations

Prostate cancer is the most common cancer in men in the Western world. Therefore, its early diagnosis in particular, which is mainly based on serum prostate-specific antigen (PSA), has gained attention in several fields of research. New biomarkers in serum and urine have been described, for example, the prostate health index (PHI) or urinary Prostate cancer gene 3 (PCA3), or others including several biomarker-based multivariate models. In addition to three studies and two reviews regarding PHI and other markers within this Special Issue "Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer", new immunoassays with the PCa-associated aberrant glycosylation of PSA (S2,3PSA) have been published. However, it is important to know not only the diagnosis, but also the prognosis or further prediction of this very common disease. Here, several new nucleic acid or protein-based tissue biomarkers have been described. Most studies in this Special Issue used tissue microarrays and immunohistochemistry. As already described for other types of cancer, individualized medicine, such as theranostics, a combination of diagnostics and therapeutics, represents a new area of interest for prostate cancer. Here, a very comprehensive review presents and discusses various important and promising kinds of nanoparticles, as well as imaging and therapy options, suitable for theranostic applications.

Table of Contents

Goodman and Hirokatsu Yoshimura Fasting Enhances the Contrast of Bone Metastatic Lesions in 18F-Fluciclovine-PET: Preclinical Study Using a Rat Model of Mixed Osteolytic/Osteoblastic Bone Metastases Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 934; doi: 10.3390/ijms18050934 -- Alison W. S. Luk, Yafeng Ma, Pei N. Ding, Francis P. Young, Wei Chua, Bavanthi Balakrishnar, Daniel T. Dransfield, Paul de Souza and Therese M. Becker CTC-mRNA (AR-V7) Analysis from Blood Samples-Impact of Blood Collection Tube and Storage Time Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 1047; doi: 10.3390/ijms18051047 -- Thorsten H. Ecke, Hui-Juan Huang-Tiel, Klaus Golka, Silvia Selinski, Berit Christine Geis, Stephan Koswig, Katrin Bathe, Steffen Hallmann and Holger Gerullis Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2016, 17(11), 1879; doi: 10.3390/ijms17111879 -- Hideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, Ken-ichi Tabata, Kouji Takenaka, Akane Sekiguchi, Masaki Nakamura, Masashi Kitano, Kazushige Hayakawa and Masatsugu Iwamura Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(1), 128; doi: 10.3390/ijms18010128.